{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T21:13:42Z","timestamp":1788556422886,"version":"build-2803163510"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Advances"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.omta.2026.201745","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T04:14:41Z","timestamp":1777608881000},"page":"201745","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A new fully closed automated banking process for healthy autologous cells to standardize the starting material for CAR T manufacturing"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5724-3669","authenticated-orcid":false,"given":"Zenghui","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4025-0176","authenticated-orcid":false,"given":"Yuanjian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangrui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoliang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qijun","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omta.2026.201745_bib1","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jcyt.2022.12.006","article-title":"Optimizing a fully automated and closed system process for red blood cell reduction of human bone marrow products","volume":"25","author":"Remley","year":"2023","journal-title":"Cytotherapy"},{"key":"10.1016\/j.omta.2026.201745_bib2","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41577-023-00982-7","article-title":"New immune cell engagers for cancer immunotherapy","volume":"24","author":"Fenis","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.omta.2026.201745_bib3","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.cell.2020.03.001","article-title":"The Emerging Landscape of Immune Cell Therapies","volume":"181","author":"Weber","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.omta.2026.201745_bib4","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev-immunol-042718-041407","article-title":"Emerging Cellular Therapies for Cancer","volume":"37","author":"Guedan","year":"2019","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.omta.2026.201745_bib5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/ejh.14076","article-title":"CAR-T cell therapy in hematological malignancies: Where are we now and where are we heading for?","volume":"112","author":"Khan","year":"2024","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.omta.2026.201745_bib6","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13045-024-01639-1","article-title":"Advances in CAR-T cell therapy for hematologic and solid malignancies: latest updates from 2024 ESMO Congress","volume":"17","author":"Huang","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.omta.2026.201745_bib7","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.omta.2026.201745_bib8","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.jcyt.2021.07.015","article-title":"Manufacturing chimeric antigen receptor T cells from cryopreserved peripheral blood cells: time for a collect-and-freeze model?","volume":"23","author":"Palen","year":"2021","journal-title":"Cytotherapy"},{"key":"10.1016\/j.omta.2026.201745_bib9","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"JCO"},{"key":"10.1016\/j.omta.2026.201745_bib10","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12979-020-0173-8","article-title":"Contributions of Age-Related Thymic Involution to Immunosenescence and Inflammaging","volume":"17","author":"Thomas","year":"2020","journal-title":"Immun. Ageing."},{"key":"10.1016\/j.omta.2026.201745_bib11","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1111\/trf.14110","article-title":"CAR-T cell manufacturing: time to put it in gear","volume":"57","author":"Bersenev","year":"2017","journal-title":"Transfusion"},{"key":"10.1016\/j.omta.2026.201745_bib12","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1182\/blood-2021-146246","article-title":"Preservation of T-Cell Stemness with a Novel Expansionless CAR-T Manufacturing Process, Which Reduces Manufacturing Time to Less Than Two Days, Drives Enhanced CAR-T Cell Efficacy","volume":"138","author":"Engels","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.omta.2026.201745_bib13","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/2326-6066.CIR-17-0405","article-title":"Reducing Ex Vivo Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells","volume":"6","author":"Ghassemi","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.omta.2026.201745_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.675179","article-title":"IL-21 Optimizes the CAR-T Cell Preparation Through Improving Lentivirus Mediated Transfection Efficiency of T Cells and Enhancing CAR-T Cell Cytotoxic Activities","volume":"8","author":"Du","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.omta.2026.201745_bib15","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/cei\/uxab038","article-title":"Reference range of na\u00efve T and T memory lymphocyte subsets in peripheral blood of healthy adult","volume":"207","author":"Xia","year":"2022","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.omta.2026.201745_bib16","doi-asserted-by":"crossref","first-page":"9363","DOI":"10.1073\/pnas.92.20.9363","article-title":"A biomarker that identifies senescent human cells in culture and in aging skin in vivo","volume":"92","author":"Dimri","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omta.2026.201745_bib17","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"The Lancet"},{"key":"10.1016\/j.omta.2026.201745_bib18","first-page":"372","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omta.2026.201745_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010709","article-title":"Prior chemotherapy deteriorates T-cell quality for CAR T-cell therapy in B-cell non-Hodgkin\u2019s lymphoma","volume":"13","author":"Herzberg","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omta.2026.201745_bib20","doi-asserted-by":"crossref","first-page":"8081","DOI":"10.1038\/s41467-024-52310-9","article-title":"A metabolomic profile of biological aging in 250,341 individuals from the UK Biobank","volume":"15","author":"Zhang","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omta.2026.201745_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0234962","article-title":"Diversity and inclusion for the All of Us research program: A scoping review","volume":"15","author":"Mapes","year":"2020","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omta.2026.201745_bib22","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1186\/s12967-019-2125-7","article-title":"Purification of viable peripheral blood mononuclear cells for biobanking using a robotized liquid handling workstation","volume":"17","author":"Coppola","year":"2019","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.omta.2026.201745_bib23","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"Off-the-shelf allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omta.2026.201745_bib24","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/s41422-022-00721-y","article-title":"Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed\/refractory CD7-positive hematological malignancies: a phase I clinical study","volume":"32","author":"Hu","year":"2022","journal-title":"Cell Res."},{"key":"10.1016\/j.omta.2026.201745_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1199145","article-title":"Strategies for overcoming bottlenecks in allogeneic CAR-T cell therapy","volume":"14","author":"Lv","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omta.2026.201745_bib34","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/labmed\/lmad073","article-title":"Single laboratory evaluation of umbilical cord blood units processing methodologies for banking","volume":"55","author":"Dos Santos","year":"2024","journal-title":"Lab. Med."},{"key":"10.1016\/j.omta.2026.201745_bib26","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3390\/vaccines11020313","article-title":"CAR-T Cells with Phytohemagglutinin (PHA) Provide Anti-Cancer Capacity with Better Proliferation, Rejuvenated Effector Memory, and Reduced Exhausted T Cell Frequencies","volume":"11","author":"Gulden","year":"2023","journal-title":"Vaccines"},{"key":"10.1016\/j.omta.2026.201745_bib27","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.18609\/cgti.2024.138","article-title":"Supporting efficacy and scaling with a next-generation T cell AOF formulation medium","volume":"10","author":"Gutowski","year":"2024","journal-title":"Cell Gene Ther. Insights"},{"key":"10.1016\/j.omta.2026.201745_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.talanta.2023.125292","article-title":"A fully automated Lab-on-a-Disc platform integrated a high-speed triggered siphon valve for PBMCs extraction","volume":"268","author":"Zhang","year":"2024","journal-title":"Talanta"},{"key":"10.1016\/j.omta.2026.201745_bib29","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jcyt.2016.11.010","article-title":"Comparison of two methodologies for the enrichment of mononuclear cells from thawed cord blood products: The automated Sepax system versus the manual Ficoll method","volume":"19","author":"Kaur","year":"2017","journal-title":"Cytotherapy"},{"key":"10.1016\/j.omta.2026.201745_bib30","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/14653240701851324","article-title":"Separation of adult bone marrow mononuclear cells using the automated closed separation system Sepax","volume":"10","author":"Aktas","year":"2008","journal-title":"Cytotherapy"},{"key":"10.1016\/j.omta.2026.201745_bib31","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1038\/s41598-025-89686-7","article-title":"Comparative analysis and process optimization for manufacturing CAR-T using the PiggyBac system derived from cryopreserved versus fresh PBMCs","volume":"15","author":"Xu","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omta.2026.201745_bib32","article-title":"Development of Ingenui-T, a Novel Vein-to-Vein Solution for Rapid Autologous CAR T-Cell Manufacturing Starting From Whole Blood, for the Treatment of Autoimmune","author":"Anaya","year":"2024","journal-title":"Diseases"},{"key":"10.1016\/j.omta.2026.201745_bib33","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.jcyt.2019.10.005","article-title":"Autologous cryopreserved leukapheresis cellular material for chimeric antigen receptor\u2013T cell manufacture","volume":"21","author":"Tyagarajan","year":"2019","journal-title":"Cytotherapy"}],"container-title":["Molecular Therapy Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X26000807?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X26000807?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T20:28:45Z","timestamp":1788553725000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3117387X26000807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S3117387X26000807"],"URL":"https:\/\/doi.org\/10.1016\/j.omta.2026.201745","relation":{},"ISSN":["3117-387X"],"issn-type":[{"value":"3117-387X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A new fully closed automated banking process for healthy autologous cells to standardize the starting material for CAR T manufacturing","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omta.2026.201745","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201745"}}